Table 14-3.05
ADAS Cog (11) - Change from Baseline to Week 16 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	24.1 (12.19)	24.4 (12.92)	21.3 (11.74)
Median (Range)	21.0 (5;61)	21.0 (5;57)	18.0 (3;57)
Week 16			
n	79	81	74
Mean (SD)	26.1 (14.16)	26.0 (13.05)	22.5 (12.33)
Median (Range)	23.0 (5;63)	25.0 (5;62)	20.0 (4;62)
Change from Baseline			
n	79	81	74
Mean (SD)	2.0 (5.89)	1.6 (4.10)	1.2 (4.33)
Median (Range)	2.0 (-17;23)	2.0 (-9;14)	1.0 (-11;13)
p-value(Dose Response) [1][2]			0.412
p-value(Xan - Placebo) [1][3]		0.724	0.392
Diff of LS Means (SE)		-0.3 (0.77)	-0.7 (0.79)
95% CI		(-1.8;1.2)	(-2.2;0.9)
p-value(Xan High - Xan Low) [1][3]			0.606
Diff of LS Means (SE)			-0.4 (0.78)
95% CI			(-1.9;1.1)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas   *21:05 Monday, June 26, 2006*